MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis

C. Dell'Aversana, C. Giorgio, L. D'Amato, G. Lania, F. Matarese, S. Saeed, A. Di Costanzo, V. Belsito Petrizzi, C. Ingenito, J. H.A. Martens, I. Pallavicini, S. Minucci, A. Carissimo, H. G. Stunnenberg, L. Altucci

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially 'immortal' state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.

Original languageEnglish
Pages (from-to)2315-2325
Number of pages11
JournalLeukemia
Volume31
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Carcinogenesis
Transcription Factors
Acute Myeloid Leukemia
Histone Deacetylase Inhibitors
MicroRNAs
Drug Resistance
Epigenomics
Cytosol
Cell Differentiation
Therapeutics
Apoptosis
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Dell'Aversana, C., Giorgio, C., D'Amato, L., Lania, G., Matarese, F., Saeed, S., ... Altucci, L. (2017). MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia, 31(11), 2315-2325. https://doi.org/10.1038/leu.2017.64

MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis. / Dell'Aversana, C.; Giorgio, C.; D'Amato, L.; Lania, G.; Matarese, F.; Saeed, S.; Di Costanzo, A.; Belsito Petrizzi, V.; Ingenito, C.; Martens, J. H.A.; Pallavicini, I.; Minucci, S.; Carissimo, A.; Stunnenberg, H. G.; Altucci, L.

In: Leukemia, Vol. 31, No. 11, 01.11.2017, p. 2315-2325.

Research output: Contribution to journalArticle

Dell'Aversana, C, Giorgio, C, D'Amato, L, Lania, G, Matarese, F, Saeed, S, Di Costanzo, A, Belsito Petrizzi, V, Ingenito, C, Martens, JHA, Pallavicini, I, Minucci, S, Carissimo, A, Stunnenberg, HG & Altucci, L 2017, 'MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis', Leukemia, vol. 31, no. 11, pp. 2315-2325. https://doi.org/10.1038/leu.2017.64
Dell'Aversana C, Giorgio C, D'Amato L, Lania G, Matarese F, Saeed S et al. MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia. 2017 Nov 1;31(11):2315-2325. https://doi.org/10.1038/leu.2017.64
Dell'Aversana, C. ; Giorgio, C. ; D'Amato, L. ; Lania, G. ; Matarese, F. ; Saeed, S. ; Di Costanzo, A. ; Belsito Petrizzi, V. ; Ingenito, C. ; Martens, J. H.A. ; Pallavicini, I. ; Minucci, S. ; Carissimo, A. ; Stunnenberg, H. G. ; Altucci, L. / MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis. In: Leukemia. 2017 ; Vol. 31, No. 11. pp. 2315-2325.
@article{278d86b95c4c431ea2e924b16520839b,
title = "MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis",
abstract = "Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially 'immortal' state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.",
author = "C. Dell'Aversana and C. Giorgio and L. D'Amato and G. Lania and F. Matarese and S. Saeed and {Di Costanzo}, A. and {Belsito Petrizzi}, V. and C. Ingenito and Martens, {J. H.A.} and I. Pallavicini and S. Minucci and A. Carissimo and Stunnenberg, {H. G.} and L. Altucci",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/leu.2017.64",
language = "English",
volume = "31",
pages = "2315--2325",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - MiR-194-5p/BCLAF1 deregulation in AML tumorigenesis

AU - Dell'Aversana, C.

AU - Giorgio, C.

AU - D'Amato, L.

AU - Lania, G.

AU - Matarese, F.

AU - Saeed, S.

AU - Di Costanzo, A.

AU - Belsito Petrizzi, V.

AU - Ingenito, C.

AU - Martens, J. H.A.

AU - Pallavicini, I.

AU - Minucci, S.

AU - Carissimo, A.

AU - Stunnenberg, H. G.

AU - Altucci, L.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially 'immortal' state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.

AB - Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially 'immortal' state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.

UR - http://www.scopus.com/inward/record.url?scp=85014587371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014587371&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.64

DO - 10.1038/leu.2017.64

M3 - Article

C2 - 28216661

AN - SCOPUS:85014587371

VL - 31

SP - 2315

EP - 2325

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -